"Antibody Drug Development in Cancer” added to ReportBuyer.com

Oct. 3, 2011 - PRLog -- ReportBuyer.com has added a new report http://www.reportbuyer.com/go/BSK00546

Summary of Report  -

This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

This report comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the antibody drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report:

The identified competitive landscape of antibody drugs in cancer is split between the 34% which have unique drug target strategies and the other part (66%) which have head-to-head target competing antibody drugs in 76 different clusters. The latter has a competing ratio which is two times higher than the comparable average of the antibody drugs in general. Contributing to this fact is heavily utilized drug target strategies like: MS4A1, ERBB2 and EGFR.

Eight out of ten drug target strategies in Phase II development are new to antibody drugs in cancer and the greatest numbers of new target strategies are found in Preclinical (30%) and Phase II development (21%).

The highest number of described target strategies among antibody drugs are found in Colorectal Cancer, Ovarian Cancer and Prostate Cancer. Antibody drugs are experiencing targeting competition in five out of every nine cancer indications described, and more so in Breast Cancer, Colorectal Cancer and non-Hodgkin's Lymphoma. Here, Ewing's Sarcoma makes out its own class by having five drugs but only towards one target strategy.
The highest number of described drug target strategies of antibody drugs belongs to Hoffmann-La Roche, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Immunomedics. However, when looking at the total number of drugs the order of the companies shifts into Hoffmann-La Roche, Immunomedics, Bristol-Myers Squibb, AstraZeneca and Eli Lilly.
From an indication perspective it is Hoffmann-La Roche, Eli Lilly, Amgen, Pfizer and Bristol-Myers Squibb which take the lead in the widest coverage of cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

Supporting development of integrative molecule, pathway and disease area strategies
Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any antibody drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others, is available at:
http://www.reportbuyer.com/pharma_healthcare/diseases/can...

# # #

Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare.